GeneReach Biotechnology Corp.
4171.TWO
Price:
$20.35
Market Cap:
$1.16B
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and research reagents and consumables. It also provides polymerase chain reaction training programs (PCR), molecular diagnostic technical solutions, laboratory installation services, OEM/ODM contract manufacturing services, and research collaboration se...[Read more]
Industry
Biotechnology
IPO Date
2012-11-19
Stock Exchange
TWO
Ticker
4171.TWO
PE Ratio
[-7.83]
ROE
[-22.70%]
Current Ratio
[2.39]
Dividend Yield
[0%]
Enterprise Value
[1.29B]
Dividend History
The ROE as of December 2025 (TTM) for GeneReach Biotechnology Corp. (4171.TWO) is -22.70%
According to GeneReach Biotechnology Corp.’s latest financial reports and current stock price. The company's current ROE is -22.70%. This represents a change of 286.99% compared to the average of -5.86% of the last 4 quarters.
GeneReach Biotechnology Corp. (4171.TWO) Historical ROE (quarterly & annually)
How has 4171.TWO ROE performed in the past?
The mean historical ROE of GeneReach Biotechnology Corp. over the last ten years is 10.93%. The current -22.70% ROE has changed -307.57% with respect to the historical average. Over the past ten years (40 quarters), 4171.TWO's ROE was at its highest in in the March 2025 quarter at -1.47%. The ROE was at its lowest in in the June 2025 quarter at -10.76%.
Average
10.93%
Median
17.31%
Minimum
-19.98%
Maximum
35.88%
GeneReach Biotechnology Corp. (4171.TWO) ROE by Quarter and Year
Discovering the peaks and valleys of GeneReach Biotechnology Corp. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 127.78%
Maximum Annual ROE = 35.88%
Minimum Annual Increase = -196.39%
Minimum Annual ROE = -19.98%
| Year | ROE | Change |
|---|---|---|
| 2024 | -16.56% | -17.13% |
| 2023 | -19.98% | -196.39% |
| 2022 | 20.73% | -42.21% |
| 2021 | 35.88% | 13.37% |
| 2020 | 31.65% | 127.78% |
GeneReach Biotechnology Corp. (4171.TWO) Average ROE
How has 4171.TWO ROE performed in the past?
The current ROE of GeneReach Biotechnology Corp. (4171.TWO) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-5.27%
5-year avg
10.34%
10-year avg
10.93%
GeneReach Biotechnology Corp. (4171.TWO) ROE vs. Peers
How is 4171.TWO’s ROE compared to its peers?
GeneReach Biotechnology Corp.’s ROE is greater than Great Novel Therapeutics Biotech & Medicals (-14.66%), greater than Enimmune corporation (-70.32%), greater than NaviFUS Corp. (-20.73%), greater than MegaPro Biomedical Co., Ltd (-91.17%), greater than Bio Preventive Medicine Corp. (-24.73%), less than BiOptic Inc. (4.93%), greater than LabTurbo Biotech Corporation (-12.54%), greater than Lukas Biomedical Inc. (-31.59%), greater than NeoCore Technology Co., Ltd. (-6.78%), greater than Excelsior Biopharma Inc. (-13.77%),
| Company | ROE | Market cap |
|---|---|---|
| -14.66% | $1.54B | |
| -70.32% | $1.58B | |
| -20.73% | $1.44B | |
| -91.17% | $950.31M | |
| -24.73% | $1.13B | |
| 4.93% | $1.37B | |
| -12.54% | $1.12B | |
| -31.59% | $1.29B | |
| -6.78% | $1.60B | |
| -13.77% | $1.34B |
Build a custom stock screener for GeneReach Biotechnology Corp. (4171.TWO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GeneReach Biotechnology Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
GeneReach Biotechnology Corp. (4171.TWO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like GeneReach Biotechnology Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is GeneReach Biotechnology Corp.'s ROE?
How is the ROE calculated for GeneReach Biotechnology Corp. (4171.TWO)?
What is the highest ROE for GeneReach Biotechnology Corp. (4171.TWO)?
What is the 3-year average ROE for GeneReach Biotechnology Corp. (4171.TWO)?
What is the 5-year average ROE for GeneReach Biotechnology Corp. (4171.TWO)?
How does the current ROE for GeneReach Biotechnology Corp. (4171.TWO) compare to its historical average?